BPC-157 vs GHK-Cu: How They Differ
BPC-157 is a 15-amino-acid peptide from a gastric juice protein, studied for repairing the gut lining, tendons and blood vessels. GHK-Cu is a three-amino-acid peptide, glycine, histidine and lysine, bound to copper, found naturally in human plasma and studied for collagen, skin and the wider tissue matrix. Both are repair peptides, but BPC-157’s research centres on blood vessel growth and connective tissue, and GHK-Cu’s on rebuilding the matrix that skin and wounds are made of. Here is how they compare and why both sit in GLOW.
Findings
- GHK-Cu was first described in 1973 from human plasma, where its level is about 200 ng/mL at age 20 and falls to 80 ng/mL by age 60 (2015 review).
- In rat wound chambers, GHK-Cu produced a concentration-dependent rise in collagen and glycosaminoglycans, with collagen synthesis stimulated twice as much as other proteins (1993).
- BPC-157 raised expression of VEGFR2, the main vascular growth factor receptor, and sped blood-flow recovery in ischaemic rat limbs (2017).
- Human data differ: GHK-Cu has 12-week cosmetic skin studies in women, BPC-157 three small pilot studies on pain and bladder symptoms.
What is BPC-157?
BPC-157 is a 15-residue partial sequence of body protection compound, a protein isolated from human gastric juice (Chang et al., J Appl Physiol, 2011). Its sequence is GEPPPGKPADDAGLV, and its developers describe it as stable in gastric juice and tested in phase II for inflammatory bowel disease (Sikiric et al., Curr Med Chem, 2012).
How BPC-157 is thought to work
Its best-documented mechanism is vascular. BPC-157 increased vessel density in chick membrane and endothelial tube assays, accelerated blood-flow recovery in ischaemic rat hind limbs, and increased VEGFR2 expression and internalisation, activating the VEGFR2, Akt and eNOS pathway (Hsieh et al., J Mol Med, 2017). In tendon, it sped the outgrowth of fibroblasts from explants, improved their survival under oxidative stress and increased their migration through FAK and paxillin signalling (Chang et al., 2011). A 2021 review from its developers covers skin wounds, deep burns, diabetic ulcers and alkali burns in rats, and reports that BPC-157 rapidly increases the expression of various genes in excision skin wounds (Seiwerth et al., Front Pharmacol, 2021).
The human studies
Three small clinical reports exist: 11 of 12 knee-pain patients given BPC-157 alone reported significant improvement (Lee and Padgett, Altern Ther Health Med, 2021); 10 of 12 women with interstitial cystitis reported complete resolution after one procedure (Lee et al., Altern Ther Health Med, 2024); and a two-person intravenous pilot found no measurable change in organ or glucose markers (Lee and Burgess, Altern Ther Health Med, 2025). A 2026 systematic review rated the certainty of this evidence very low (Poolton et al., Acta Orthop Belg, 2026).
What is GHK-Cu?
GHK is a tripeptide, glycyl-histidyl-lysine, present in human plasma, saliva and urine, and it is proposed to work as a complex with copper, which is why the research form is GHK-Cu (Pickart et al., Biomed Res Int, 2015). It was isolated by Loren Pickart in 1973 from human plasma. The 2015 review puts plasma GHK at about 200 ng/mL at age 20, falling to 80 ng/mL by age 60, and links the decline to the loss of regenerative capacity with age. The copper is also why the powder and solution are blue, explained in Why GHK-Cu is blue.
The wound and matrix research
The key animal study implanted wire-mesh wound chambers under the skin of rats and injected them with saline or GHK-Cu. GHK-Cu produced a concentration-dependent increase in dry weight, DNA, total protein, collagen and glycosaminoglycans; collagen synthesis rose twice as much as non-collagen protein, and type I and type III collagen messenger RNA increased, while a control tripeptide had no significant effect (Maquart et al., J Clin Invest, 1993). Reviews from the peptide’s discoverer describe it stimulating both the synthesis and the breakdown of collagen and glycosaminoglycans, attracting immune and endothelial cells to injuries, and modulating the activity of at least 4,000 human genes in gene-expression data (Pickart et al., 2015; Pickart and Margolina, Int J Mol Sci, 2018).
The human skin studies
GHK-Cu’s human data come from cosmetic studies summarised in the 2015 review. When creams were applied to the thigh for a month, skin biopsies showed increased collagen in 70% of women using GHK-Cu, against 50% with vitamin C and 40% with retinoic acid. A GHK-Cu facial cream used for 12 weeks by 71 women with mild to advanced photoageing improved laxity and clarity, reduced fine lines and wrinkle depth, and increased skin density and thickness; a second 12-week study in 67 women aged 50 to 59 reported similar gains (Pickart et al., 2015). A 2026 primer found no clinical data for musculoskeletal use (Mayfield et al., Am J Sports Med, 2026). More is in GHK-Cu: the skin research.
How do BPC-157 and GHK-Cu compare side by side?
| Question | BPC-157 | GHK-Cu |
|---|---|---|
| What is it? | Partial sequence of a gastric juice protein | Natural plasma tripeptide bound to copper |
| Size | 15 amino acids | 3 amino acids plus copper |
| Main research areas | Gut lining, tendon, ligament, blood vessels | Skin, collagen, wound matrix, hair |
| Mechanism focus | VEGFR2, Akt and eNOS; FAK and paxillin | Collagen and glycosaminoglycan synthesis; copper delivery; gene expression |
| Human evidence | Three small pilot studies, 30 people | 12-week cosmetic skin studies in women |
| Forms we supply | 10 mg vial, nasal spray, blends | 50 mg and 100 mg vials, nasal spray, blends |
Which one fits which research question?
- Skin ageing, collagen density and photodamage: GHK-Cu, the compound with the human skin studies.
- Wound matrix composition, collagen types I and III: GHK-Cu, from the wound-chamber work.
- Tendon, ligament and gut lining repair: BPC-157, with its tendon fibroblast and colitis models.
- New vessel growth in ischaemic tissue: BPC-157, from the VEGFR2 hind-limb work.
Can BPC-157 and GHK-Cu be studied together?
Yes. The rationale is that one supplies the blood supply and the other the matrix: BPC-157’s research covers vessel growth and connective tissue, GHK-Cu’s covers collagen and glycosaminoglycan production. Because the mechanisms differ, a study using both keeps two distinguishable variables, a rationale built from each compound’s own literature rather than a combined trial.
Both are in GLOW, together with TB-500, and KLOW adds KPV; the choice is laid out in KLOW vs GLOW and GHK-Cu vs GLOW. For GHK-Cu against the third tripeptide, see KPV vs GHK-Cu.
How are BPC-157 and GHK-Cu supplied?
BPC-157 comes as a 10 mg lyophilised vial and the ready-mixed BPC-157 Nasal Spray; GHK-Cu as 50 mg and 100 mg vials and the GHK-Cu Nasal Spray, both sprays metered at 0.175 mL per press. Vials are reconstituted with bacteriostatic water: see the BPC-157 and GHK-Cu reconstitution guides, and how long GHK-Cu lasts for storage, including why it is kept dark. Certificates of analysis are on the lab reports page, and every order ships from within Canada.
BPC-157 and GHK-Cu are supplied for laboratory research use only. The human studies above used clinical preparations or cosmetic formulations.
Frequently asked questions
What is the difference between BPC-157 and GHK-Cu?
BPC-157 is a 15-amino-acid partial sequence of a gastric juice protein, studied for gut, tendon and blood vessel repair. GHK-Cu is a natural three-amino-acid plasma peptide bound to copper, studied for collagen production, skin and wound matrix.
Which is better for skin research, BPC-157 or GHK-Cu?
GHK-Cu has the skin-specific human data: in 12-week studies of 71 and 67 women, GHK-Cu creams improved skin density, thickness and fine lines. BPC-157’s skin work is in rat wound and burn models.
Can BPC-157 and GHK-Cu be studied together?
Yes. BPC-157 research covers vessel growth and connective tissue, GHK-Cu research covers collagen and matrix, so a study using both keeps two distinguishable variables. Both are in the GLOW and KLOW blends.
Why is GHK-Cu blue?
The colour comes from the copper(II) ion bound to the GHK peptide, the Cu2+ in its full chemical name, glycyl-L-histidyl-L-lysine-Cu2+.
Where can I buy BPC-157 and GHK-Cu in Canada?
Vistara Labs supplies BPC-157 as a 10 mg vial and nasal spray, GHK-Cu as 50 mg and 100 mg vials and a nasal spray, and both together in GLOW and KLOW, shipped from within Canada by Canada Post Xpresspost.
Product details from vistaralabs.ca, October 2026. Sources: Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID 21030672. Sikiric P et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012. PMID 22300085. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017. PMID 27847966. Seiwerth S et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021. PMID 34267654. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PMID 34324435. Lee E et al. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PMID 39325560. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PMID 40131143. Poolton JT et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PMID 42885452. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PMID 26236730. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018. PMID 29986520. Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. PMID 8227353. Mayfield CK et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. PMID 41476424.
More on this: Peptides for Skin: What the Research Shows.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
